| Species |
Human |
| Protein Construction |
DPPIV/CD26 (Asn29-Pro766)
Accession # P27487 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized DPPIV/CD26, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiDPPIV Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its ability to cleave the fluorogenic peptide substrate, GlyPro7amido4methylcoumarin (GPAMC). The specific activity is >8500 pmol/min/µg. Test result meets thestandard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
86.39 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 90-115 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD26/dipeptidyl peptidase (DPP)IV is a membrane-bound protein found in many cell types of the body, and a soluble form is present in body fluids. There is longstanding evidence that various primary tumors and also metastases express DPPIV/CD26 to a variable extent. |
| Synonyms |
ADCP2; CD26; DPPIV; DPP4; ADABP; TP103; EC 3.4.14.5 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
